
Shares in Fagron FAGRO.BR rise 4.9% after the Belgian pharmaceuticals producer reported better-than-expected FY results
KBC securities says Fagron delivered a solid FY25 performance, with revenue coming in 1% above consensus expectations, mainly supported by better-than-expected growth
in North America
The broker adds that the FY REBITDA reached €193m, coming in 1.6% above CSS expectations, as all regions reported slightly higher margins than anticipated
"This is a good set of results, underpinned by solid, robust organic growth and disciplined execution" - KBC
Share on track for a best day since April 2025, when it closed 5.9% higher
Up to the previous session's close, shares were up 1.4% YTD